Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress
Provided By GlobeNewswire
Last update: May 8, 2025
Topline data from multiple Phase 2 studies expected throughout 2025
• Q2 readout from VTX3232 study in patients with early Parkinson’s disease
Read more at globenewswire.com3.92
-0.08 (-2%)
Find more stocks in the Stock Screener
VTYX Latest News and Analysis
